AI Article Synopsis
- - Influenza A and B viruses lead to serious health issues and deaths globally each year, with neuraminidase inhibitors (NAIs) being the primary antiviral treatment for infections.
- - Research shows that influenza B viruses are not as responsive to oseltamivir and other NAIs as influenza A viruses, indicating less effectiveness in treating B infections.
- - The analysis of clinical studies reveals lower effectiveness of oseltamivir for patients with influenza B compared to those with influenza A, but there is insufficient data on other NAIs like zanamivir, laninamivir, and peramivir to draw firm conclusions about their effectiveness against each type.
Article Abstract
Influenza A and B viruses cause significant morbidity and mortality worldwide each year. The neuraminidase inhibitors (NAIs) are the most commonly used class of influenza antiviral drugs for the treatment of infected patients. In vitro studies have shown that influenza B viruses are significantly less susceptible to oseltamivir and other neuraminidase inhibitors compared with influenza A viruses. Following analysis of published clinical studies, we show that oseltamivir does appear to have lower effectiveness in patients infected with influenza B virus compared with influenza A infected patients, but due to insufficient studies on zanamivir, laninamivir or peramivir, it was not possible to conclude the relative effectiveness of these drugs against influenza A virus compared with B virus.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/14787210.2013.842466 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!